

COVINGTON & BURLING LLP

1201 PENNSYLVANIA AVENUE NW
WASHINGTON, DC 20004-2401
TEL 202.662.6000
FAX 202.662.6291
WWW.COV.COM

BEIJING
BRUSSELS
LONDON
NEW YORK
SAN DIEGO
SAN FRANCISCO
SILICON VALLEY
WASHINGTON

MICHAEL S. LABSON
TEL 202.662.5220
FAX 202.778.5220
MLABSON@COV.COM

April 5, 2011

BY EMAIL AND U.S. MAIL

Laurie Lenkel
Director, Office of the Ombudsman
U.S. Food and Drug Administration
10903 New Hampshire Avenue
WO 32, Room 4260
Silver Spring, Maryland 20993

Re: Docket No. FDA-2010-N-0621; Avastin®

Dear Ms. Lenkel:

I am writing on behalf of Genentech, Inc. ("Genentech") in response to the February 23, 2011 and March 10, 2011 letters from Karen Midthun, M.D., Presiding Officer, requesting that the parties identify whether they expect to submit confidential information as part of the proceedings in the above-referenced matter.

Genentech does not intend to claim confidential commercial information or trade secret status for any of the information it has submitted to the docket or intends to present at the hearing in this matter. Please note that Genentech does not waive any applicable confidentiality or trade secret protection for any other information regarding Avastin submitted to or in the possession of the FDA.

Respectfully submitted,



Michael S. Labson
Counsel for Genentech, Inc.

cc: Carla Cartwright, Office of the Chief Counsel, Food and Drug Administration
Donald Beers, Office of the Chief Counsel, Food and Drug Administration